How China’s deep-pocketed pivot helped startups survive the “capital winter”

Founders recount a freeze-and-thaw survival story

It has been reported that an end‑of‑year feature compiled by Xianfeng (险峰) and published on Huxiu collected conversations with six founders about how they navigated the 2024–25 capital winter. The dominant lesson? When global private capital pulled back, many Chinese deep‑tech teams found survival in pragmatism: stop overbuilding, lean on manufacturing partners and, increasingly, seek domestic state capital. Sound boring? For some founders it was the difference between bankruptcy and profitability.

From a failed factory bet to a working joint venture

One founder told of a near‑fatal decision to build an entire factory in‑house — from upstream feedstock to downstream coating — and then watching budgets overrun by roughly 30% and delivery slip six months. Investors reportedly put due diligence on hold, saying they wanted to “see how founders react in crisis,” which left the company under 1 million RMB and staff largely working unpaid while the landlord deferred rent. Rescue came in 2025 via a 51/49 joint venture with a listed manufacturer: the startup kept technical control but used the partner’s mature lines, began mass shipments within months, and reached cash‑flow breakeven by October and profitability by early 2026. High‑profile customers — including Anta (安踏) — have since validated the pivot, the founder says.

A broader, geopolitical shift toward RMB‑led manufacturing

Founders also described a wider industry pivot. Synthetic biology and spatial omics were long USD‑centric, venture‑backed narratives; after several high‑profile US‑led failures (Gingo Membranes, reportedly) and tighter Western technology controls, Beijing’s 15th Five‑Year planning tilt elevated bio‑manufacturing and pushed commercialization toward Chinese factories and RMB financing. That matters geopolitically: sanctions and trade policy have reshaped where scale gets built and who pays for it. The message to foreign readers is clear — China’s comparative advantage remains manufacturing scale, and many founders now benchmark themselves to Wanhua (万华) or BASF (巴斯夫), not to Silicon Valley unicorns. The takeaway for entrepreneurs? Long‑termism, careful capital allocation and partnering with domestic industrial players can outlast a capital winter.